{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:22:05Z","timestamp":1747207325319,"version":"3.40.5"},"reference-count":80,"publisher":"Bentham Science Publishers Ltd.","issue":"8","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>The novel coronavirus disease-19 (COVID-19) is a global pandemic that emerged from\nWuhan, China, and has spread all around the world, affecting 216 countries or territories with\n21,732,472 people infected and 770,866 deaths globally (as per WHO COVID-19 updates of August\n18, 2020). Continuous efforts are being made to repurpose the existing drugs and develop vaccines for\ncombating this infection. Despite, to date, no certified antiviral treatment or vaccine exists. Although,\nfew candidates have displayed their efficacy in in vitro studies and are being repurposed for COVID-\n19 treatment. This article summarizes synthetic and semi-synthetic compounds displaying potent activity\nin clinical uses or studies on COVID-19 and also focuses on the mode of action of drugs being\nrepositioned against COVID-19.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389557520666201204162103","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T07:24:56Z","timestamp":1607153096000},"page":"1004-1016","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Synthetic and Semi-synthetic Drugs as a Promising Therapeutic Option for the Treatment of COVID-19"],"prefix":"10.2174","volume":"21","author":[{"given":"Ekta","family":"Shirbhate","sequence":"first","affiliation":[{"name":"Institute of Pharmaceutical Sciences, Guru Ghasidas University, Bilaspur 495 009, C.G.,India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preeti","family":"Patel","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Sciences, Guru Ghasidas University, Bilaspur 495 009, C.G.,India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay K","family":"Patel","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Sciences, Guru Ghasidas University, Bilaspur 495 009, C.G.,India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravichandran","family":"Veerasamy","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, AIMST University, Semeling, 08100 Bedong, Kedah Darul Aman,Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabodh C","family":"Sharma","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra 136 119, Haryana,India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barij N","family":"Sinha","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Birla Institute of Technology, Mesra - Ranchi-835 215, Jharkhand,India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2008-2827","authenticated-orcid":true,"given":"Harish","family":"Rajak","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Sciences, Guru Ghasidas University, Bilaspur 495 009, C.G.,India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/jmv.25766","volume":"92","author":"He F.","year":"2020","unstructured":"He F.; Deng Y.; Li W.; Coronavirus disease 2019: What we know? J Med Virol 2020,92(7),719-725","journal-title":"J Med Virol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/JCMA.0000000000000270","volume":"83","author":"Wu Y.C.","year":"2020","unstructured":"Wu Y.C.; Chen C.S.; Chan Y.J.; The outbreak of COVID-19: An overview. J Chin Med Assoc 2020,83(3),217-220","journal-title":"J Chin Med Assoc"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jaut.2020.102433","author":"Rothan H.A.","year":"2020","unstructured":"Rothan H.A.; Byrareddy S.N.; The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020,109","journal-title":"J Autoimmun"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"Lu R.","year":"2020","unstructured":"Lu R.; Zhao X.; Li J.; Niu P.; Yang B.; Wu H.; Wang W.; Song H.; Huang B.; Zhu N.; Bi Y.; Ma X.; Zhan F.; Wang L.; Hu T.; Zhou H.; Hu Z.; Zhou W.; Zhao L.; Chen J.; Meng Y.; Wang J.; Lin Y.; Yuan J.; Xie Z.; Ma J.; Liu W.J.; Wang D.; Xu W.; Holmes E.C.; Gao G.F.; Wu G.; Chen W.; Shi W.; Tan W.; Genomic characterization and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 2020,395(10224),565-574","journal-title":"Lancet"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"Zhou P.","year":"2020","unstructured":"Zhou P.; Yang X.L.; Wang X.G.; Hu B.; Zhang L.; Zhang W.; Si H.R.; Zhu Y.; Li B.; Huang C.L.; Chen H.D.; Chen J.; Luo Y.; Guo H.; Jiang R.D.; Liu M.Q.; Chen Y.; Shen X.R.; Wang X.; Zheng X.S.; Zhao K.; Chen Q.J.; Deng F.; Liu L.L.; Yan B.; Zhan F.X.; Wang Y.Y.; Xiao G.F.; Shi Z.L.; A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020,579(7798),270-273","journal-title":"Nature"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"Zhu N.","year":"2020","unstructured":"Zhu N.; Zhang D.; Wang W.; Li X.; Yang B.; Song J.; Zhao X.; Huang B.; Shi W.; Lu R.; Niu P.; Zhan F.; Ma X.; Wang D.; Xu W.; Wu G.; Gao G.F.; Tan W.; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020,382(8),727-733","journal-title":"N Engl J Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.12688\/f1000research.22211.2","volume":"9","author":"Kruse R.L.","year":"2020","unstructured":"Kruse R.L.; Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000 Res 2020,9,72","journal-title":"F1000 Res"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.coviro.2015.06.009","volume":"13","author":"Gretebeck L.M.","year":"2015","unstructured":"Gretebeck L.M.; Subbarao K.; Animal models for SARS and MERS coronaviruses. Curr Opin Virol 2015,13,123-129","journal-title":"Curr Opin Virol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/path.4454","volume":"235","author":"Gralinski L.E.","year":"2015","unstructured":"Gralinski L.E.; Baric R.S.; Molecular pathology of emerging coronavirus infections. J Pathol 2015,235(2),185-195","journal-title":"J Pathol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1056\/NEJMoa030747","volume":"348","author":"Drosten C.","year":"2003","unstructured":"Drosten C.; G\u00fcnther S.; Preiser W.; van der Werf S.; Brodt H.R.; Becker S.; Rabenau H.; Panning M.; Kolesnikova L.; Fouchier R.A.M.; Berger A.; Burgui\u00e8re A.M.; Cinatl J.; Eickmann M.; Escriou N.; Grywna K.; Kramme S.; Manuguerra J.C.; M\u00fcller S.; Rickerts V.; St\u00fcrmer M.; Vieth S.; Klenk H.D.; Osterhaus A.D.; Schmitz H.; Doerr H.W.; Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003,348(20),1967-1976","journal-title":"N Engl J Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrd.2015.37","volume":"15","author":"Zumla A.","year":"2016","unstructured":"Zumla A.; Chan J.F.; Azhar E.I.; Hui D.S.; Yuen K.Y.; Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov 2016,15(5),327-347","journal-title":"Nat Rev Drug Discov"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1080\/21645515.2020.1735227","volume":"16","author":"Dhama K.","year":"2020","unstructured":"Dhama K.; Sharun K.; Tiwari R.; Dadar M.; Malik Y.S.; Singh K.P.; Chaicumpa W.; COVID-19, an emerging coronavirus infection: Advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccin Immunother 2020,16(6),1232-1238","journal-title":"Hum Vaccin Immunother"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/jmv.25707","volume":"92","author":"Zhang L.","year":"2020","unstructured":"Zhang L.; Liu Y.; Potential interventions for novel coronavirus in China: A systematic review. J Med Virol 2020,92(5),479-490","journal-title":"J Med Virol"},{"key":"ref=14","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117477","volume":"248","author":"Elfiky A.A.","year":"2020","unstructured":"Elfiky A.A.; Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci 2020,248","journal-title":"Life Sci"},{"key":"ref=15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105955","volume":"55","author":"Zhai P.","year":"2020","unstructured":"Zhai P.; Ding Y.; Wu X.; Long J.; Zhong Y.; Li Y.; The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents 2020,55(5)","journal-title":"Int J Antimicrob Agents"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3390\/v12040372","volume":"12","author":"Jin Y.","year":"2020","unstructured":"Jin Y.; Yang H.; Ji W.; Wu W.; Chen S.; Zhang W.; Duan G.; Virology, epidemiology, pathogenesis and control of COVID-19. Viruses 2020,12(4),372","journal-title":"Viruses"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"Huang C.","year":"2020","unstructured":"Huang C.; Wang Y.; Li X.; Ren L.; Zhao J.; Hu Y.; Zhang L.; Fan G.; Xu J.; Gu X.; Cheng Z.; Yu T.; Xia J.; Wei Y.; Wu W.; Xie X.; Yin W.; Li H.; Liu M.; Xiao Y.; Gao H.; Guo L.; Xie J.; Wang G.; Jiang R.; Gao Z.; Jin Q.; Wang J.; Cao B.; Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020,395(10223),497-506","journal-title":"Lancet"},{"key":"ref=18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105948","volume":"55","author":"Wang L.","year":"2020","unstructured":"Wang L.; Wang Y.; Ye D.; Liu Q.; Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. Int J Antimicrob Agents 2020,55(6)","journal-title":"Int J Antimicrob Agents"},{"key":"ref=19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105945","volume":"55","author":"Sahraei Z.","year":"2020","unstructured":"Sahraei Z.; Shabani M.; Shokouhi S.; Saffaei A.; Aminoquinolines against coronavirus disease 2019 (COVID-19): Chloroquine or hydroxychloroquine. Int J Antimicrob Agents 2020,55(4)","journal-title":"Int J Antimicrob Agents"},{"key":"ref=20","author":"Smith T.","year":"2020","unstructured":"Smith T.; Bushek J.; Prosser T.;  COVID-19 Drug therapy 2020","journal-title":"COVID-19 Drug therapy"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jcrc.2020.03.005","volume":"57","author":"Cortegiani A.","year":"2020","unstructured":"Cortegiani A.; Ingoglia G.; Ippolito M.; Giarratano A.; Einav S.; A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 2020,57,279-283","journal-title":"J Crit Care"},{"key":"ref=22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105938","volume":"55","author":"Devaux C.A.","year":"2020","unstructured":"Devaux C.A.; Rolain J.M.; Colson P.; Raoult D.; New insights on the antiviral effects of chloroquine against coronavirus: What to expect for COVID-19? Int J Antimicrob Agents 2020,55(5)","journal-title":"Int J Antimicrob Agents"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","volume":"3","author":"Savarino A.","year":"2003","unstructured":"Savarino A.; Boelaert J.R.; Cassone A.; Majori G.; Cauda R.; Effects of chloroquine on viral infections: An old drug against today\u2019s diseases? Lancet Infect Dis 2003,3(11),722-727","journal-title":"Lancet Infect Dis"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.dsx.2020.03.011","volume":"14","author":"Singh A.K.","year":"2020","unstructured":"Singh A.K.; Singh A.; Shaikh A.; Singh R.; Misra A.; Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr 2020,14(3),241-246","journal-title":"Diabetes Metab Syndr"},{"key":"ref=25","first-page":"4539","volume":"24","author":"Meo S.A.","year":"2020","unstructured":"Meo S.A.; Klonoff D.C.; Akram J.; Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. Eur Rev Med Pharmacol Sci 2020,24(8),4539-4547","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/jmv.25729","volume":"92","author":"Yao T.T.","year":"2020","unstructured":"Yao T.T.; Qian J.D.; Zhu W.Y.; Wang Y.; Wang G.Q.; A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. J Med Virol 2020,92(6),556-563","journal-title":"J Med Virol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"769","DOI":"10.2165\/00003495-200363080-00004","volume":"63","author":"Cvetkovic R.S.","year":"2003","unstructured":"Cvetkovic R.S.; Goa K.L.; Lopinavir\/ritonavir: A review of its use in the management of HIV infection. Drugs 2003,63(8),769-802","journal-title":"Drugs"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.2165\/00003495-200060060-00009","volume":"60","author":"Hurst M.","year":"2000","unstructured":"Hurst M.; Faulds D.; Lopinavir. Drugs 2000,60(6),1371-1379","journal-title":"Drugs"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1128\/AAC.03011-14","volume":"58","author":"de Wilde A.H.","year":"2014","unstructured":"de Wilde A.H.; Jochmans D.; Posthuma C.C.; Zevenhoven-Dobbe J.C.; van Nieuwkoop S.; Bestebroer T.M.; van den Hoogen B.G.; Neyts J.; Snijder E.J.; Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 2014,58(8),4875-4884","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2147\/TCRM.S3285","volume":"4","author":"Chandwani A.","year":"2008","unstructured":"Chandwani A.; Shuter J.; Lopinavir\/ritonavir in the treatment of HIV-1 infection: A review. Ther Clin Risk Manag 2008,4(5),1023-1033","journal-title":"Ther Clin Risk Manag"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1128\/AAC.00840-06","volume":"51","author":"Skinner-Adams T.S.","year":"2007","unstructured":"Skinner-Adams T.S.; Andrews K.T.; Melville L.; McCarthy J.; Gardiner D.L.; Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro. Antimicrob Agents Chemother 2007,51(2),759-762","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4103\/ijmr.IJMR_504_20","volume":"151","author":"Bhatnagar T.","year":"2020","unstructured":"Bhatnagar T.; Murhekar M.V.; Soneja M.; Gupta N.; Giri S.; Wig N.; Gangakhedkar R.; Lopinavir\/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use. Indian J Med Res 2020,151(2 - 3),184-189","journal-title":"Indian J Med Res"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"13823","DOI":"10.5812\/archcid.13823","volume":"12","author":"Dayer M.R.","year":"2017","unstructured":"Dayer M.R.; Taleb-Gassabi S.; Dayer M.S.; Lopinavir: A potent drug against coronavirus infection: Insight from molecular docking study. Arch Clin Infect Dis 2017,12,13823","journal-title":"Arch Clin Infect Dis"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5582\/bst.2020.01020","volume":"14","author":"Lu H.","year":"2020","unstructured":"Lu H.; Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends 2020,14(1),69-71","journal-title":"Biosci Trends"},{"key":"ref=35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105951","volume":"55","author":"Li H.","year":"2020","unstructured":"Li H.; Liu S.M.; Yu X.H.; Tang S.L.; Tang C.K.; Coronavirus disease 2019 (COVID-19): Current status and future perspectives. Int J Antimicrob Agents 2020,55(5)","journal-title":"Int J Antimicrob Agents"},{"key":"ref=36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105933","volume":"55","author":"Ko W.C.","year":"2020","unstructured":"Ko W.C.; Rolain J.M.; Lee N.Y.; Chen P.L.; Huang C.T.; Lee P.I.; Hsueh P.R.; Arguments in favour of remdesivir for treating SARS-CoV-2 infections. Int J Antimicrob Agents 2020,55(4)","journal-title":"Int J Antimicrob Agents"},{"year":"2019","unstructured":"Coronavirus disease2019 http:\/\/en.m.wikipedia.org\/wiki\/Coronavirus_disease_2019","key":"ref=37"},{"unstructured":"Coronavirus (COVID-19) update: FDA issues emergency use authorization for potential COVID-19 Treatment.  https:\/\/www.fda.gov\/news-events\/pressannouncements\/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment","key":"ref=38"},{"unstructured":"Coronavirus (COVID-19) update: FDA warns of newly discovered potential drug interaction that may reduce effectiveness of a COVID- 19 treatment authorized for emergency use.  https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-updatefda-warns-newlydiscovered-potential-drug-interaction-may-reduce","key":"ref=39"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2183\/pjab.93.027","volume":"93","author":"Furuta Y.","year":"2017","unstructured":"Furuta Y.; Komeno T.; Nakamura T.; Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad, Ser B, Phys Biol Sci 2017,93(7),449-463","journal-title":"Proc Jpn Acad, Ser B, Phys Biol Sci"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40779-020-00240-0","volume":"7","author":"Guo Y.R.","year":"2020","unstructured":"Guo Y.R.; Cao Q.D.; Hong Z.S.; Tan Y.Y.; Chen S.D.; Jin H.J.; Tan K.S.; Wang D.Y.; Yan Y.; The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - An update on the status. Mil Med Res 2020,7(1),11","journal-title":"Mil Med Res"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00044-016-1533-y","volume":"25","author":"Elfiky A.A.","year":"2016","unstructured":"Elfiky A.A.; Elshemey W.M.; IDX-184 is a superior HCV direct-acting antiviral drug: A QSAR study. Med Chem Res 2016,25(5),1005-1008","journal-title":"Med Chem Res"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jinf.2020.03.002","volume":"81","author":"Deng L.","year":"2020","unstructured":"Deng L.; Li C.; Zeng Q.; Liu X.; Li X.; Zhang H.; Hong Z.; Xia J.; Arbidol combined with LPV\/r versus LPV\/r alone against Corona Virus Disease 2019: A retrospective cohort study. J Infect 2020,81(1),e1-e5","journal-title":"J Infect"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"997","DOI":"10.2174\/092986708784049658","volume":"15","author":"Boriskin Y.S.","year":"2008","unstructured":"Boriskin Y.S.; Leneva I.A.; P\u00e9cheur E.I.; Polyak S.J.; Arbidol: A broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem 2008,15(10),997-1005","journal-title":"Curr Med Chem"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1021\/acs.jcim.0c00179","volume":"60","author":"Wang J.","year":"2020","unstructured":"Wang J.; Fast identification of possible drug treatment of coronavirus disease (COVID-19) through computational drug repurposing study. J Chem Inf Model 2020,60(6),3277-3286","journal-title":"J Chem Inf Model"},{"key":"ref=46","first-page":"9","volume":"53","author":"Khamitov R.A.","year":"2008","unstructured":"Khamitov R.A.; Loginova S.Ia.; Shchukina V.N.; Borisevich S.V.; Maksimov V.A.; Shuster A.M.; Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures. Vopr Virusol 2008,53(4),9-13","journal-title":"Vopr Virusol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"615","DOI":"10.2217\/fvl.11.33","volume":"6","author":"Barnard D.L.","year":"2011","unstructured":"Barnard D.L.; Kumaki Y.; Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy. Future Virol 2011,6(5),615-631","journal-title":"Future Virol"},{"key":"ref=48","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117592","volume":"253","author":"Elfiky A.A.","year":"2020","unstructured":"Elfiky A.A.; Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci 2020,253","journal-title":"Life Sci"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","volume":"19","author":"Li G.","year":"2020","unstructured":"Li G.; De Clercq E.; Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 2020,19(3),149-150","journal-title":"Nat Rev Drug Discov"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/jmv.25752","volume":"92","author":"Cimolai N.","year":"2020","unstructured":"Cimolai N.; Potentially repurposing adamantanes for COVID-19. J Med Virol 2020,92(6),531-532","journal-title":"J Med Virol"},{"key":"ref=51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105944","volume":"55","author":"Baron S.A.","year":"2020","unstructured":"Baron S.A.; Devaux C.; Colson P.; Raoult D.; Rolain J.M.; Teicoplanin: An alternative drug for the treatment of COVID-19? Int J Antimicrob Agents 2020,55(4)","journal-title":"Int J Antimicrob Agents"},{"key":"ref=52","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2020.110011","volume":"144","author":"Sathyamoorthy N.","year":"2020","unstructured":"Sathyamoorthy N.; Chintamaneni P.K.; Chinni S.; Plausible role of combination of Chlorpromazine hydrochloride and Teicoplanin against COVID-19. Med Hypotheses 2020,144","journal-title":"Med Hypotheses"},{"key":"ref=53","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.05.935387","author":"Zhang J.","year":"2020","unstructured":"Zhang J.; Ma X.; Yu F.; Liu J.; Zou F.; Pan T.; Zhang H.; Teicoplanin potently blocks the cell entry of 2019-nCoV. Biorxiv 2020","journal-title":"Biorxiv"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"9218","DOI":"10.1074\/jbc.M116.716100","volume":"291","author":"Zhou N.","year":"2016","unstructured":"Zhou N.; Pan T.; Zhang J.; Li Q.; Zhang X.; Bai C.; Huang F.; Peng T.; Zhang J.; Liu C.; Tao L.; Zhang H.; Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome\/lysosome and block the entry of Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J Biol Chem 2016,291(17),9218-9232","journal-title":"J Biol Chem"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ijantimicag.2016.07.004","volume":"48","author":"Colson P.","year":"2016","unstructured":"Colson P.; Raoult D.; Fighting viruses with antibiotics: An overlooked path. Int J Antimicrob Agents 2016,48(4),349-352","journal-title":"Int J Antimicrob Agents"},{"key":"ref=56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105949","volume":"56","author":"Gautret P.","year":"2020","unstructured":"Gautret P.; Lagier J.C.; Parola P.; Hoang V.T.; Meddeb L.; Mailhe M.; Doudier B.; Courjon J.; Giordanengo V.; Vieira V.E.; Tissot Dupont H.; Honor\u00e9 S.; Colson P.; Chabri\u00e8re E.; La Scola B.; Rolain J.M.; Brouqui P.; Raoult D.; Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020,56(1)","journal-title":"Int J Antimicrob Agents"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"14408","DOI":"10.1073\/pnas.1618029113","volume":"113","author":"Retallack H.","year":"2016","unstructured":"Retallack H.; Di Lullo E.; Arias C.; Knopp K.A.; Laurie M.T.; Sandoval-Espinosa C.; Mancia Leon W.R.; Krencik R.; Ullian E.M.; Spatazza J.; Pollen A.A.; Mandel-Brehm C.; Nowakowski T.J.; Kriegstein A.R.; DeRisi J.L.; Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc Natl Acad Sci USA 2016,113(50),14408-14413","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1021\/acsinfecdis.5b00030","volume":"1","author":"Madrid P.B.","year":"2015","unstructured":"Madrid P.B.; Panchal R.G.; Warren T.K.; Shurtleff A.C.; Endsley A.N.; Green C.E.; Kolokoltsov A.; Davey R.; Manger I.D.; Gilfillan L.; Bavari S.; Tanga M.J.; Evaluation of Ebola virus inhibitors for drug repurposing. ACS Infect Dis 2015,1(7),317-326","journal-title":"ACS Infect Dis"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4172\/1948-5964.1000173","volume":"10","author":"Bosseboeuf E.","year":"2018","unstructured":"Bosseboeuf E.; Aubry M.; Nhan T.; De Pina J.J.; Rolain J.M.; Raoult D.; Musso D.; Azithromycin inhibits the replication of Zika virus. J Antivir Antiretrovir 2018,10(1),6-11","journal-title":"J Antivir Antiretrovir"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1001\/jama.2015.13896","volume":"314","author":"Bacharier L.B.","year":"2015","unstructured":"Bacharier L.B.; Guilbert T.W.; Mauger D.T.; Boehmer S.; Beigelman A.; Fitzpatrick A.M.; Jackson D.J.; Baxi S.N.; Benson M.; Burnham C.D.; Cabana M.; Castro M.; Chmiel J.F.; Covar R.; Daines M.; Gaffin J.M.; Gentile D.A.; Holguin F.; Israel E.; Kelly H.W.; Lazarus S.C.; Lemanske R.F.; Ly N.; Meade K.; Morgan W.; Moy J.; Olin T.; Peters S.P.; Phipatanakul W.; Pongracic J.A.; Raissy H.H.; Ross K.; Sheehan W.J.; Sorkness C.; Szefler S.J.; Teague W.G.; Thyne S.; Martinez F.D.; Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: A randomized clinical trial. JAMA 2015,314(19),2034-2044","journal-title":"JAMA"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1021\/acsinfecdis.0c00052","volume":"6","author":"Xu J.","year":"2020","unstructured":"Xu J.; Shi P.Y.; Li H.; Zhou J.; Broad spectrum antiviral agent niclosamide and its therapeutic potential. ACS Infect Dis 2020,6(5),909-915","journal-title":"ACS Infect Dis"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"a105","DOI":"10.1093\/ofid\/ofaa105","volume":"7","author":"McCreary E.K.","year":"2020","unstructured":"McCreary E.K.; Pogue J.M.; Coronavirus disease 2019 treatment: A review of early and emerging options. Open Forum Infect Dis 2020,7(4),a105","journal-title":"Open Forum Infect Dis"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1001\/jama.2020.4812","volume":"323","author":"Patel A.B.","year":"2020","unstructured":"Patel A.B.; Verma A.; COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: What is the evidence? JAMA 2020,323(18),1769-1770","journal-title":"JAMA"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1021\/acscentsci.0c00272","volume":"6","author":"Liu C.","year":"2020","unstructured":"Liu C.; Zhou Q.; Li Y.; Garner L.V.; Watkins S.P.; Carter L.J.; Smoot J.; Gregg A.C.; Daniels A.D.; Jervey S.; Albaiu D.; Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus disease. ACS Cent Sci 2020,6(3),315-331","journal-title":"ACS Cent Sci"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/ddr.21656","volume":"81","author":"Gurwitz D.","year":"2020","unstructured":"Gurwitz D.; Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res 2020,81(5),537-540","journal-title":"Drug Dev Res"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/ddr.21666","volume":"81","author":"Phadke M.","year":"2020","unstructured":"Phadke M.; Saunik S.; COVID-19 treatment by repurposing drugs until the vaccine is in sight. Drug Dev Res 2020,81(5),541-543","journal-title":"Drug Dev Res"},{"author":"Boseley S.","unstructured":"Boseley S.; Recovery trial for Covid-19 treatments: What we know so far.  https:\/\/www.theguardian.com\/world\/2020\/jun\/16\/recovery-trial-for-covid-19-treatments-what-we-know-so-far","key":"ref=67"},{"unstructured":"WHO welcomes preliminary results about dexamethasone use in treating critically ill COVID-19 patients.  https:\/\/www.who.int\/news-room\/detail\/16-06-2020-who-welcomes-preliminary-results-about-dexamethasone-use-in-treating-critically-ill-covid-19-patients","key":"ref=68"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/d41586-020-00751-9","volume":"579","author":"Jiang S.","year":"2020","unstructured":"Jiang S.; Don\u2019t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees. Nature 2020,579(7799),321","journal-title":"Nature"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"72","DOI":"10.5582\/bst.2020.01047","volume":"14","author":"Gao J.","year":"2020","unstructured":"Gao J.; Tian Z.; Yang X.; Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020,14(1),72-73","journal-title":"Biosci Trends"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.antiviral.2020.104762","author":"Touret F.","year":"2020","unstructured":"Touret F.; de Lamballerie X.; Of chloroquine and COVID-19. Antiviral Res 2020,177","journal-title":"Antiviral Res"},{"key":"ref=72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105932","volume":"55","author":"Colson P.","year":"2020","unstructured":"Colson P.; Rolain J.M.; Lagier J.C.; Brouqui P.; Raoult D.; Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020,55(4)","journal-title":"Int J Antimicrob Agents"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"Wang M.","year":"2020","unstructured":"Wang M.; Cao R.; Zhang L.; Yang X.; Liu J.; Xu M.; Shi Z.; Hu Z.; Zhong W.; Xiao G.; Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020,30(3),269-271","journal-title":"Cell Res"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/cid\/ciaa237","volume":"71","author":"Yao X.","year":"2020","unstructured":"Yao X.; Ye F.; Zhang M.; Cui C.; Huang B.; Niu P.; Liu X.; Zhao L.; Dong E.; Song C.; Zhan S.; Lu R.; Li H.; Tan W.; Liu D.; In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020,71(15),732-739","journal-title":"Clin Infect Dis"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.tmaid.2020.101615","author":"Al-Tawfiq J.A.","year":"2020","unstructured":"Al-Tawfiq J.A.; Al-Homoud A.H.; Memish Z.A.; Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis 2020,34","journal-title":"Travel Med Infect Dis"},{"key":"ref=76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105969","volume":"55","author":"Serafin M.B.","year":"2020","unstructured":"Serafin M.B.; Bottega A.; Foletto V.S.; da Rosa T.F.; H\u00f6rner A.; H\u00f6rner R.; Drug repositioning is an alternative for the treatment of coronavirus COVID-19. Int J Antimicrob Agents 2020,55(6)","journal-title":"Int J Antimicrob Agents"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ijid.2019.01.041","volume":"81","author":"Arabi Y.M.","year":"2019","unstructured":"Arabi Y.M.; Deeb A.M.; Al-Hameed F.; Mandourah Y.; Almekhlafi G.A.; Sindi A.A.; Al-Omari A.; Shalhoub S.; Mady A.; Alraddadi B.; Almotairi A.; Al Khatib K.; Abdulmomen A.; Qushmaq I.; Solaiman O.; Al-Aithan A.M.; Al-Raddadi R.; Ragab A.; Al Harthy A.; Kharaba A.; Jose J.; Dabbagh T.; Fowler R.A.; Balkhy H.H.; Merson L.; Hayden F.G.; Macrolides in critically ill patients with Middle East Respiratory Syndrome. Int J Infect Dis Saudi Critical Care Trials group2019,81,184-190","journal-title":"Int J Infect Dis"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.2174\/1389450121666200617133142","volume":"21","author":"Al-Bari M.A.A.","year":"2020","unstructured":"Al-Bari M.A.A.; Facts and myths: Efficacies of repurposing chloroquine and hydroxychloroquine for the treatment of COVID-19. Curr Drug Targets 2020,21,1703-1721","journal-title":"Curr Drug Targets"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"534","DOI":"10.2174\/1389200221666200711160440","volume":"21","author":"Yao X.","year":"2020","unstructured":"Yao X.; Hou Z.; Cui C.; Zhang M.; Tu S.; Li H.; Liu D.; Updates on the pharmacology of chloroquine against Coronavirus disease 2019 (COVID-19): A perspective on its use in the general and geriatric population. Curr Drug Metab 2020,21,534-540","journal-title":"Curr Drug Metab"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.2174\/0929867327666200416131117","volume":"27","author":"Costanzo M.","year":"2020","unstructured":"Costanzo M.; De Giglio M.A.R.; Roviello G.N.; SARS-CoV-2: Recent reports on antiviral therapies based on lopinavir\/ritonavir, darunavir\/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus. Curr Med Chem 2020,27(27),4536-4541","journal-title":"Curr Med Chem"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389557520666201204162103","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/188739\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389557520666201204162103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T07:51:38Z","timestamp":1660463498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/188739\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":80,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389557520666201204162103","relation":{},"ISSN":["1389-5575"],"issn-type":[{"type":"print","value":"1389-5575"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-07-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}